STOCK TITAN

Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on precision dermatology, reported Q2 2024 financial results and provided business updates. Key highlights include:

1. Completed a $10 million follow-on offering, extending cash runway into 2025.
2. Strengthened global IP portfolio with new patents.
3. Presented positive preclinical data for ATR-04 and ATR-12.
4. Opened Phase 1b trial for ATR-12 in Netherton Syndrome.
5. Anticipates dosing first Netherton syndrome patient with ATR-12 in Q3 2024.
6. Expects to file and clear IND for ATR-04 in Q3 2024.
7. Plans to report initial ATR-12 Phase 1b safety data by year-end 2024.
8. Aims to dose first patient with ATR-04 for EGFRi rash by year-end 2024.
9. Expects topline data from ATR-12 Phase 1b trial in mid-2025.

Financial results: Q2 2024 service revenue $7,500, R&D expenses $1.1M, G&A expenses $1.5M, net loss $2.6M. Cash and equivalents as of June 30, 2024: $0.8M.

Azitra, Inc. (NYSE American: AZTR), un'azienda biofarmaceutica in fase clinica focalizzata sulla dermatologia di precisione, ha riportato i risultati finanziari del secondo trimestre 2024 e fornito aggiornamenti aziendali. I punti salienti includono:

1. Completamento di un'offerta follow-on da 10 milioni di dollari, prolungando la liquidità fino al 2025.
2. Rafforzamento del portafoglio IP globale con nuovi brevetti.
3. Presentati dati preclinici positivi per ATR-04 e ATR-12.
4. Apertura della sperimentazione di Fase 1b per ATR-12 nella Sindrome di Netherton.
5. Anticipa la somministrazione del primo paziente con sindrome di Netherton con ATR-12 nel terzo trimestre 2024.
6. Si aspetta di presentare e ottenere l'approvazione della IND per ATR-04 nel terzo trimestre 2024.
7. Prevede di riportare i dati di sicurezza iniziali di ATR-12 Fase 1b entro la fine del 2024.
8. Mira a somministrare il primo paziente con ATR-04 per eritema indotto da EGFRi entro la fine del 2024.
9. Si aspetta dati preliminari dalla sperimentazione di Fase 1b di ATR-12 a metà del 2025.

Risultati finanziari: entrate da servizi nel Q2 2024 di $7.500, spese R&S di $1,1 milioni, spese G&A di $1,5 milioni, perdita nette di $2,6 milioni. Liquidità e equivalenti al 30 giugno 2024: $0,8 milioni.

Azitra, Inc. (NYSE American: AZTR), una empresa biofarmacéutica en etapa clínica centrada en la dermatología de precisión, informó los resultados financieros del segundo trimestre de 2024 y brindó actualizaciones sobre el negocio. Los aspectos destacados incluyen:

1. Completada una oferta de seguimiento por 10 millones de dólares, extendiendo la disponibilidad de efectivo hasta 2025.
2. Fortalecimiento de la cartera de propiedad intelectual global con nuevas patentes.
3. Presentados datos preclínicos positivos para ATR-04 y ATR-12.
4. Abierto el ensayo de fase 1b para ATR-12 en el síndrome de Netherton.
5. Anticipa la dosificación del primer paciente con síndrome de Netherton con ATR-12 en el tercer trimestre de 2024.
6. Espera presentar y obtener la aprobación de la IND para ATR-04 en el tercer trimestre de 2024.
7. Planea informar los datos de seguridad iniciales de ATR-12 fase 1b antes de finalizar 2024.
8. Apunta a dosificar al primer paciente con ATR-04 para la erupción por EGFRi antes de finalizar 2024.
9. Espera datos preliminares del ensayo de fase 1b de ATR-12 a mediados de 2025.

Resultados financieros: ingresos por servicios del Q2 2024 de $7,500, gastos de I+D de $1.1M, gastos de G&A de $1.5M, pérdida neta de $2.6M. Efectivo y equivalentes al 30 de junio de 2024: $0.8M.

Azitra, Inc. (NYSE American: AZTR)는 정밀 피부과에 중점을 둔 임상 단계의 생명공학 회사로, 2024년 2분기 재무 결과 및 사업 업데이트를 보고했습니다. 주요 사항은 다음과 같습니다:

1. 1천만 달러의 후속 공모를 완료하여 2025년까지 자금 조달을 연장했습니다.
2. 새로운 특허로 글로벌 IP 포트폴리오를 강화했습니다.
3. ATR-04 및 ATR-12에 대한 긍정적인 전임상 데이터를 발표했습니다.
4. 네세르톤 증후군을 위한 ATR-12의 1b상 시험을 개시했습니다.
5. 2024년 3분기에는 ATR-12로 첫 번째 네세르톤 증후군 환자에게 투여할 예정입니다.
6. 2024년 3분기에 ATR-04에 대한 IND를 제출하고 승인받기를 예상합니다.
7. 2024년 말까지 ATR-12 1b상의 초기 안전성 데이터를 보고할 계획입니다.
8. 2024년 말까지 EGFRi 발진으로 ATR-04의 첫 환자를 투여할 목표입니다.
9. 2025년 중반에 ATR-12 1b상 시험의 주요 데이터가 예상됩니다.

재무 결과: 2024년 2분기 서비스 수익 7,500달러, R&D 비용 110만 달러, G&A 비용 150만 달러, 순손실 260만 달러. 2024년 6월 30일 현재 현금 및 현금성 자산: 80만 달러.

Azitra, Inc. (NYSE American: AZTR), une entreprise biopharmaceutique en phase clinique axée sur la dermatologie de précision, a communiqué ses résultats financiers du deuxième trimestre 2024 et des mises à jour sur ses activités. Les points saillants comprennent :

1. Achèvement d'une offre de suivi de 10 millions de dollars, prolongeant la liquidité jusqu'en 2025.
2. Renforcement du portefeuille PI mondial avec de nouveaux brevets.
3. Présentation de données précliniques positives pour ATR-04 et ATR-12.
4. Ouverture de l'essai de phase 1b pour ATR-12 dans le syndrome de Netherton.
5. Anticipe l'administration du premier patient atteint du syndrome de Netherton avec ATR-12 au troisième trimestre 2024.
6. S'attend à déposer et obtenir l'IND pour ATR-04 au troisième trimestre 2024.
7. Prévoyez de communiquer les données de sécurité initiales d'ATR-12 Phase 1b d'ici la fin de 2024.
8. Vise à administrer le premier patient avec ATR-04 pour l'éruption d'EGFRi d'ici la fin de 2024.
9. S'attend à des données de haut niveau de l'essai de phase 1b d'ATR-12 à la mi-2025.

Résultats financiers : revenus de services pour le 2e trimestre 2024 de 7 500 $, dépenses de R&D de 1,1 million $, dépenses de G&A de 1,5 million $, perte nette de 2,6 millions $. Liquidités et équivalents au 30 juin 2024 : 0,8 million $.

Azitra, Inc. (NYSE American: AZTR), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf präzise Dermatologie konzentriert, hat die finanziellen Ergebnisse für das zweite Quartal 2024 veröffentlicht und Einblicke in das Unternehmen gegeben. Die wichtigsten Punkte sind:

1. Abschluss einer Folgeplatzierung in Höhe von 10 Millionen Dollar, die die finanzielle Grundlage bis 2025 verlängert.
2. Stärkung des globalen IP-Portfolios durch neue Patente.
3. Präsentation positiver präklinischer Daten für ATR-04 und ATR-12.
4. Eröffnung der Phase-1b-Studie für ATR-12 im Netherton-Syndrom.
5. Erwartet die Dosierung des ersten Netherton-Syndrom-Patienten mit ATR-12 im dritten Quartal 2024.
6. Erwarten, die IND für ATR-04 im dritten Quartal 2024 einzureichen und zu genehmigen.
7. Planen, bis Ende 2024 erste Sicherheitsdaten der ATR-12 Phase 1b zu berichten.
8. Ziel, bis Ende 2024 den ersten Patienten mit ATR-04 für EGFRi-Ausschlag zu dosieren.
9. Erwarten Anfangsdaten aus der ATR-12 Phase 1b Studie Mitte 2025.

Finanzergebnisse: Dienstleistungsumsatz im Q2 2024 von $7.500, F&E-Ausgaben von $1,1 Millionen, G&A-Ausgaben von $1,5 Millionen, Nettoverlust von $2,6 Millionen. Bargeld und Äquivalente zum 30. Juni 2024: $0,8 Millionen.

Positive
  • Completed $10 million follow-on offering, extending cash runway into 2025
  • Strengthened global intellectual property portfolio with new patents
  • Presented positive preclinical data for ATR-04 and ATR-12
  • Opened Phase 1b clinical trial for ATR-12 in Netherton Syndrome
  • Anticipates filing and clearing IND for ATR-04 in Q3 2024, expanding clinical pipeline
  • Expects to initiate first-in-human clinical trial for ATR-04 in EGFRi rash by year-end 2024
  • Plans to report topline data from ATR-12 Phase 1b trial in mid-2025
Negative
  • Service revenue decreased from $172,000 in Q2 2023 to $7,500 in Q2 2024
  • R&D expenses increased from $0.8M in Q2 2023 to $1.1M in Q2 2024
  • G&A expenses increased from $0.8M in Q2 2023 to $1.5M in Q2 2024
  • Net loss of $2.6M in Q2 2024
  • Cash and cash equivalents of only $0.8M as of June 30, 2024

Insights

Azitra's Q2 2024 results reveal a mixed financial picture. The company's $10 million follow-on offering provides a cash runway into 2025, but the $0.8 million cash position as of June 30 is concerning. Revenue dropped significantly from $172,000 to $7,500 year-over-year, while R&D and G&A expenses increased. The net loss narrowed from $5.1 million to $2.6 million, but this improvement seems primarily due to non-operational factors. Investors should closely monitor cash burn and potential dilution risks.

Azitra's pipeline progress is promising. The initiation of ATR-12's Phase 1b trial for Netherton syndrome and the planned IND filing for ATR-04 targeting EGFRi rash demonstrate clinical advancement. Positive preclinical data for both candidates is encouraging. The anticipated topline data from ATR-12's Phase 1b trial in mid-2025 could be a significant catalyst. However, investors should note that early-stage clinical trials carry substantial risks and success is not guaranteed.

Azitra's focus on precision dermatology addresses niche markets with high unmet needs. The Netherton syndrome and EGFRi rash indications represent specialized opportunities with potentially less competition. The continuation of the Bayer collaboration adds credibility to Azitra's platform. However, the 95.6% year-over-year decline in service revenue is concerning and warrants explanation. Investors should assess the company's ability to monetize its pipeline and secure additional partnerships to support long-term growth.

BRANFORD, Conn.--(BUSINESS WIRE)-- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended June 30, 2024, and provided a business update.

Q2 2024 and Recent Business Highlights

  • Completed a follow-on offering of $10 million in gross proceeds expected to provide cash runway into 2025. With the recent financing, the company anticipates announcing multiple clinical milestones
  • Strengthened global intellectual property portfolio with newly granted and allowed patents
  • Exhibited positive preclinical data from ATR-04 at the Society of Investigative Dermatology Annual Meeting
  • Presented positive preclinical data of ATR-12 and clinical design in Netherton Syndrome at the ASGCT Annual Meeting
  • Opened a Phase 1b clinical trial for ATR-12 for recruitment

Francisco Salva, CEO of Azitra commented:

“Azitra is poised to achieve significant milestones in the second half of 2024 and beyond, propelling our pipeline forward. In Q3 2024, we expect to dose the first Netherton syndrome patient with ATR-12. Additionally, we anticipate filing and clearing an Investigational New Drug (IND) application for ATR-04, targeting epidermal growth factor receptor inhibitor (EGFRi) rash, a condition with high unmet need. This milestone will expand our clinical pipeline to two clinical-stage programs.

Approximately year-end 2024, we anticipate reporting initial safety data from the ATR-12 Phase 1b trial in Netherton syndrome patients and providing an update on our Bayer license agreement. We expect to initiate a first-in-human clinical trial with ATR-04 for EGFRi rash this fall.

Looking ahead to mid-2025, we eagerly anticipate reporting topline data from the ATR-12 Phase 1b trial, a defining moment as we aim to demonstrate biological proof of concept of our innovative approach in addressing this severe, rare skin disorder.

With a clear roadmap, strong financial position, and dedicated team, Azitra is well-positioned to execute these milestones, deliver transformative therapies to patients in need, and ultimately maximize shareholder value.”

Pipeline and Upcoming Milestones

  • Q3 2024: First Netherton syndrome patient dosed with ATR-12
  • Q3 2024: New investigational new drug (IND) application filed and cleared with the FDA for a Phase 1/2 clinical study of ATR-04 in patients with dermal toxicity undergoing treatment with EGFR inhibitors (“EGFRi rash”)
  • YE 2024: Initial safety data from first set of Netherton syndrome patients in the Phase 1b trial
  • YE 2024: First patient dosed with ATR-04 for EGFRi rash by year end 2024
  • YE 2024: Bayer collaboration continues with update on license agreement expected by year end
  • Mid 2025: Topline data of the Phase 1b trial with ATR-12 in Netherton syndrome patients expected

Financial Results for the Three Months Ended June 30, 2024

  • Service Revenue – Related Party: The Company generated $7,500 service revenue during the quarter ended June 30, 2024, compared to $172,000 for the comparable period in 2023.
  • Research and Development (R&D) expenses: R&D expenses for the quarter ended June 30, 2024, were $1.1 million compared to $0.8 million for the comparable period in 2023.
  • General and Administrative (G&A) expenses: G&A expenses for the quarter ended June 30, 2024, were $1.5 million compared to $0.8 million for the comparable period in 2023.
  • Net Loss was $2.6 million for the quarter ended June 30, 2024, compared to $5.1 million for the comparable period in 2023.
  • Cash and cash equivalents: As of June 30, 2024, the Company had cash and cash equivalents of $0.8 million.

About ATR-12

ATR-12 (also known as ATR12-351) is an engineered strain of S. epidermidis that expresses a fragment of human lympho-epithelial Kazal-type-related inhibitor (LEKTI) protein, which is missing in patients with Netherton syndrome, a chronic and sometimes fatal disease of the skin estimated to affect approximately 20,000 patients globally. ATR-12 has been engineered to deliver missing LEKTI protein when applied topically to Netherton syndrome patients. Azitra has an open IND for a Phase 1b clinical trial that is actively recruiting adult Netherton syndrome patients (NCT06137157). Azitra has identified Netherton syndrome patients for enrollment in its 12-patient, Phase 1b clinical trial, which will assess safety, tolerability, and efficacy endpoints.

About ATR-04

ATR-04 is a live biotherapeutic product candidate including an isolated, naturally derived S. epidermidis strain that was engineered to be safer by deleting an antibiotic resistance gene and engineering auxotrophy to control the growth of ATR-04. ATR-04 is in development for EGFR inhibitor (“EGFRi”) associated rash, which is caused by the suppression of skin immunity by EGFRis and subsequent inflammation and often elevated levels of IL-36γ and S. aureus. There are approximately 150,000 patients suffering from EGFRi rash in the United States. Azitra plans to initiate a Phase 1/2 clinical study in patients undergoing EGFRi rash by year end 2024.

About Azitra, Inc.

Azitra, Inc. is an early-stage clinical biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. The Company has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen the Company’s library of strains for drug like molecules. The Company’s initial focus is on the development of genetically engineered strains of Staphylococcus epidermidis, or S. epidermidis, which the Company considers to be an optimal therapeutic candidate species for engineering of dermatologic therapies. For more information, please visit https://azitrainc.com/.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding the expected timing of the presentation of data from the Phase 1b study of ATR-12, the filing of an IND application, and the presentation of data from our Phase 1b for ATR-04, the IND filing for ATR-01, the timing of having a signed license agreement with Bayer, and statements about our clinical and pre-clinical programs, and corporate and clinical/pre-clinical strategies.

Any forward-looking statements in this press release are based on current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to that we may fail to successfully complete our Phase 1b trial for ATR-12 and pre-clinical studies of other product candidates and obtain required approval before commercialization; our product candidates may not be effective; there may be delays in regulatory approval or changes in regulatory framework that are out of our control; our estimation of addressable markets of our product candidates may be inaccurate; we may fail to timely raise additional required funding; more efficient competitors or more effective competing treatment may emerge; we may be involved in disputes surrounding the use of our intellectual property crucial to our success; we may not be able to attract and retain key employees and qualified personnel; earlier study results may not be predictive of later stage study outcomes; and we are dependent on third-parties for some or all aspects of our product manufacturing, research and preclinical and clinical testing. Additional risks concerning Azitra’s programs and operations are described in its registration statement on Form S-1, which is on file with the SEC, and in its most recent quarterly report on Form 10-Q to be filed with the SEC. Azitra explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Condensed Statement of Operations

(Unaudited)

 

 

 

Three months Ended June 30,

 

 

2024

 

2023

Service revenue – related party

 

$

7,500

 

 

$

172,000

 

Total revenue

 

 

7,500

 

 

 

172,000

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

General and administrative

 

 

1,549,228

 

 

 

844,639

 

Research and development

 

 

1,118,552

 

 

 

754,951

 

Total operating expenses

 

 

2,667,780

 

 

 

1,599,590

 

 

 

 

 

 

 

 

Loss from operations

 

 

(2,660,280

)

 

 

(1,427,590

)

 

 

 

 

 

 

 

Other income (expense):

 

 

 

 

 

 

Interest income

 

 

16,268

 

 

 

264

 

Interest expense

 

 

(1,782

)

 

 

(76,187

)

Change in fair value of convertible note

 

 

-

 

 

 

(2,830,100

)

Change in fair value of warrants

 

 

4,272

 

 

 

(94,232

)

Other income (expense)

 

 

9,529

 

 

 

(1,683

)

Total other income (expense)

 

 

28,287

 

 

 

(3,001,938

)

 

 

 

 

 

 

 

Net loss before income taxes

 

 

(2,631,993

)

 

 

(4,429,528

)

 

 

 

 

 

 

 

Income tax expense

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

Net loss

 

$

(2,631,993

)

 

 

(4,429,528

)

Dividends on preferred stock

 

 

-

 

 

 

(643,267

)

Net loss attributable to common shareholders

 

$

(2,631,993

)

 

 

(5,072,795

)

Net loss per Share, basic and diluted

 

$

(2.74

)

 

$

(70.83

)

Weighted average common stock outstanding, basic and diluted

 

 

960,146

 

 

 

71,622

 

Condensed Balance Sheets

(Unaudited)

 

 

 

June 30,

 

December 31,

 

 

2024

 

2023

Assets

 

 

 

 

Current Assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

803,082

 

 

$

1,795,989

 

Other receivables

 

 

111,895

 

 

 

223,474

 

Prepaid expenses and other current assets

 

 

420,828

 

 

 

516,116

 

Total current assets

 

$

1,335,805

 

 

$

2,535,579

 

Property and equipment, net

 

658,731

 

 

 

710,075

 

Other assets

 

 

1,888,018

 

 

 

1,869,832

 

Total assets

 

$

3,882,554

 

 

$

5,115,486

 

Liabilities, and stockholders’ equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

996,700

 

 

$

897,272

 

Current financing lease liability

 

 

15,317

 

 

 

14,600

 

Current operating lease liability

 

 

293,026

 

 

 

307,655

 

Accrued expenses

 

 

434,103

 

 

 

383,668

 

Total current liabilities

 

 

1,739,146

 

 

 

1,603,195

 

Long-term financing lease liability

 

 

18,329

 

 

 

26,169

 

Long-term operating lease liability

 

 

395,987

 

 

 

537,523

 

Warrant liability

 

 

2,926

 

 

 

35,453

 

Total liabilities

 

 

2,156,388

 

 

 

2,202,340

 

Stockholders’ equity

 

 

 

 

 

 

Common stock

 

 

96

 

 

 

40

 

Additional paid-in capital

 

 

55,889,271

 

 

 

51,510,269

 

Accumulated deficit

 

 

(54,163,201

)

 

 

(48,597,163

)

Total stockholders’ equity

 

 

1,726,166

 

 

 

2,913,146

 

Total liabilities and stockholders’ equity

 

$

3,882,554

 

 

$

5,115,486

 

 

Norman Staskey

Chief Financial Officer

staskey@azitrainc.com

Hayden IR

James Carbonara

(646) 755-7412

james@haydenir.com

Source: Azitra, Inc.

FAQ

What were Azitra's (AZTR) Q2 2024 financial results?

Azitra (AZTR) reported Q2 2024 service revenue of $7,500, R&D expenses of $1.1M, G&A expenses of $1.5M, and a net loss of $2.6M. The company had $0.8M in cash and cash equivalents as of June 30, 2024.

What are the key upcoming milestones for Azitra (AZTR) in 2024?

Key milestones for Azitra (AZTR) in 2024 include: dosing the first Netherton syndrome patient with ATR-12 in Q3, filing and clearing an IND for ATR-04 in Q3, reporting initial ATR-12 Phase 1b safety data by year-end, and dosing the first patient with ATR-04 for EGFRi rash by year-end.

How much did Azitra (AZTR) raise in its recent follow-on offering?

Azitra (AZTR) completed a follow-on offering of $10 million in gross proceeds, which is expected to extend the company's cash runway into 2025.

When does Azitra (AZTR) expect to report topline data from the ATR-12 Phase 1b trial?

Azitra (AZTR) anticipates reporting topline data from the ATR-12 Phase 1b trial in Netherton syndrome patients by mid-2025.

Azitra Inc

NYSE:AZTR

AZTR Rankings

AZTR Latest News

AZTR Stock Data

4.20M
7.63M
10.7%
8.92%
3.12%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BRANFORD